Treatment of metastatic esophagus and gastric cancer Journal Article
| Authors: | Shah, M. A.; Schwartz, G. K. |
| Article Title: | Treatment of metastatic esophagus and gastric cancer |
| Abstract: | Cancers of the upper gastrointestinal tract include cancers of the esophagus, gastroesophageal junction, and stomach. Metastatic or unresectable upper gastrointestinal malignancies are incurable but do benefit from palliative chemotherapy. Several agents have been examined in the treatment of these diseases, with modest single-agent activity. In combination, these chemotherapeutic agents demonstrate improved antitumor activity with acceptable toxicity. Several combination therapies have been developed and have been examined in recent large phase III randomized clinical trials. These studies, for the most part, have failed to demonstrate a survival advantage over the reference arm. However, with the examination of newer cytotoxic agents, as well as with the application of molecularly targeted approaches to upper gastrointestinal malignancies, there remains hope for improved therapies for these diseases in the future. © 2004 Elsevier Inc. All rights reserved. |
| Keywords: | cancer chemotherapy; cancer survival; treatment outcome; treatment failure; clinical trial; fatigue; neutropenia; review; cancer localization; cisplatin; doxorubicin; fluorouracil; cancer combination chemotherapy; cancer risk; diarrhea; drug efficacy; treatment planning; antineoplastic agents; capecitabine; gemcitabine; paclitaxel; methotrexate; topotecan; antineoplastic agent; cancer palliative therapy; palliative care; imatinib; disease association; carboplatin; unindexed drug; metastasis; bortezomib; bone marrow suppression; etoposide; blood toxicity; nausea; neuropathy; stomatitis; vomiting; palliative therapy; pathology; vinblastine; docetaxel; irinotecan; death; folinic acid; gefitinib; neoplasm metastasis; bleomycin; stomach cancer; epirubicin; mitomycin c; vindesine; taxane derivative; anthracycline derivative; dna topoisomerase inhibitor; navelbine; mitomycin; oxaliplatin; esophagus cancer; lethargy; stomach neoplasms; fluoropyrimidine derivative; clinical trials; esophagus tumor; esophageal neoplasms; lower esophagus sphincter; stomach tumor; tegafur; raltitrexed; uracil; humans; prognosis; human; priority journal |
| Journal Title: | Seminars in Oncology |
| Volume: | 31 |
| Issue: | 4 |
| ISSN: | 0093-7754 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2004-08-01 |
| Start Page: | 574 |
| End Page: | 587 |
| Language: | English |
| DOI: | 10.1053/j.seminoncol.2004.04.013 |
| PROVIDER: | scopus |
| PUBMED: | 15297948 |
| DOI/URL: | |
| Notes: | Semin. Oncol. -- Cited By (since 1996):46 -- Export Date: 16 June 2014 -- CODEN: SOLGA -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work